Chemicals & Small Molecules

Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin).

Tabituximab (ONC-005) is a humanized monoclonal antibody targeting frizzled class receptor 10 (FZD10) with antitumor activity for the study of immune system diseases.

Necitumumab (IMC-11F8) is a human monoclonal antibody directed against the epidermal growth factor (EGF) receptor, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer, and may be used in cancer research.

PF-03732010 is a CHO-expressed humanized antibody targeting P-calmodulin with anti-tumor and anti-metastatic activity, inhibiting primary tumor growth and metastatic progression.

Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.

Icatolimab (JS-004) is a humanized antibody targeting BTLA/CD272 for the study of lymphomas and solid tumors.

LCKLSL hydrochloride is a hexapeptide compound and competitive inhibitor of membrane-bound protein A2 (AnxA2) with potential anti-angiogenic activity that inhibits the development of autoimmune encephalomyelitis (EAE) in mice.

MOG peptide (35-55) amide, a myelin oligodendrocyte glycoprotein (MOG) fragment spanning amino acids 35 to 55, selectively stimulates CD4+ T cell expansion and induces experimental autoimmune encephalomyelitis (EAE) in animal models [1] [2] [3].

ELOVL6-IN-1 is a potent, selective, and orally active inhibitor of ELOVL6, exhibiting dose-dependent inhibition of mouse ELOVL6 with an IC50 of 0.350 μM and acting as a noncompetitive inhibitor with respect to malonyl-CoA (Ki=994 nM) and palmitoyl-CoA [1].